Astrana Health, Inc. filed a Current Report on Form 8-K with the U.S. Securities and Exchange Commission on September 15, 2026, to disclose an updated corporate presentation. The filing states that the company intends to use the attached Investor Presentation, dated September 2026, during conferences and meetings.
The presentation outlines the company’s strategy for 2026, focusing on its delegated financial model and an AI-native operating platform. Astrana describes its model as replacing healthcare fragmentation with a coordinated operating system that integrates primary care, multi-specialty providers, and hospitals. The company claims this ecosystem allows members to stay within the network across different payers and lines of business.
The filing details the benefits of Astrana’s delegated risk-bearing organization (RBO) structure. It notes that this model provides visibility, control, and economic alignment compared to standard fee-for-service arrangements. The presentation highlights that Astrana partners with approximately 20 other payers to help them bend the cost curve, reduce Medical Cost Ratio (MCR) volatility, and achieve higher quality.
A significant portion of the presentation is dedicated to the company’s artificial intelligence capabilities. Astrana describes an application layer featuring agents for Prior Auth, Claims Adjudication, and Patient Engagement. The company claims to have a unified data layer that harmonizes data from EMRs, Health Information Exchanges (HIE), and claims data to power these AI tools.
The company reports on its operational scale, stating it has proven its model across 16 markets nationwide. It cites internal data and CMS benchmarks to illustrate outcomes, including a 14% shorter inpatient length of stay compared to the benchmark and 67% fewer hospital admissions. Additionally, the presentation notes that approximately 70% of prior authorizations are auto-approved.
The filing includes standard forward-looking statements and a section explaining the use of non-GAAP financial measures such as EBITDA, Adjusted EBITDA, and free cash flow. The company defines these measures and notes that reconciliations to GAAP measures are provided in an appendix, though specific forward-looking reconciliations are not provided due to inherent uncertainties.
